Moderna shares slide on concerns over drop in RSV vaccine efficacy, ET HealthWorld

New Delhi:

Moderna fell as much as 7 per cent on Friday after Wall Street analysts raised concerns over faster declines in the efficacy of its experimental respiratory syncytial virus (RSV) vaccine when compared with rival shots from GSK and Pfizer.

Data posted on Thursday ahead of an RSV conference next week showed an efficacy of about 63 per cent after 8.6 months in preventing RSV-related respiratory disease, down from 84 per cent at 3.3 months.

Moderna’s shares fell to $89 in morning trading, after closing down 5.7 per cent on Thursday.

Brokerages TD Cowen and UBS said the data raised questions that the vaccine could show a steeper decline at another long term follow-up of 14 months, giving competitors an edge.

The efficacy for GSK’s vaccine, called Arexvy, fell to 77 per cent at 14 months from 83 per cent, while Pfizer’s slipped to 49 per cent in 17 months from 67 per cent, according to TD Cowen.

Moderna cautioned against comparing its vaccine, saying the trials for the rival shots used different case definitions for RSV-disease.

“In the absence of head-to-head clinical trials, comparative conclusions regarding the safety and efficacy of mRNA-1345 relative to other RSV vaccines cannot be made,” Moderna said.

Despite the differences, TD Cowen analyst Tyler Van Buren said in a note it raises concerns over the competitive profile of Moderna’s shot if confirmed with more data.

GSK and Pfizer launched their shots last year.

While no final decision has been made for how often the vaccines should be given, GSK and Pfizer are both looking at the possibility of at least two years of efficacy.

The RSV vaccine is one of the key products Moderna is banking on to revive sales as demand declines sharply for COVID-19 shots.

  • Published On Feb 10, 2024 at 12:26 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles

Scan to download App

Leave a Reply

Your email address will not be published. Required fields are marked *